Newsletter | September 26, 2023

09.26.23 -- Using AI In Drug Discovery Isn't The Golden Solution You Think It Is — Yet


Using AI In Drug Discovery Isn’t The Golden Solution You Think It Is — Yet.

Before we realize the true potential of advanced artificial intelligence (AI) and machine learning (ML) technologies to treat disease, we need to start by developing technologies that can generate the massive amounts of reliable, high-quality biological data that make up the fundamentals of any AI/ML approach.


Harness High-Quality PBPK Modeling To Enhance Clinical Readiness

Advancements in PBPK modeling are enabling drug sponsors to identify poor absorption properties early in development, helping them to mitigate risk in their preclinical and clinical studies.

How Collaborative Value Engineering Enhances The CDMO Relationship

Regular assessments of a partnership’s value in terms of supply chain, operational efficiency, data analysis, and more can optimize and extend the product life cycle.

Simultaneous Spray Drying For Large/Small Molecule Combinations

Gain insights into a “simul-spray” process pioneering for combining small and large molecules into a single, atomized drug product for inhalation administration.

Defining A Process For Your Unique mRNA

Define a process for your unique mRNA with this interactive guide to pDNA, mRNA, and LNP. Overcome challenges with solutions that can help you develop a next-generation production strategy.

Approaching IND: What To Consider In Early Development

When preparing for IND submission, developers must consider multiple components. Explore tips for optimizing early development programs and the benefits of housing all activities under one roof.

Addressing Key Challenges Of High-Concentration Formulation Development

High-concentration formulations often present challenges with regard to viscosity as well as potential changes in the behavior upon stability. Discover solutions to mitigate high viscosity.



Orexo Submits NDA To FDA For OX124, A High-Dose Rescue Med For Opioid Overdose

Charles River & Related Sciences Enter Multi-Program Collaboration

Lantern Pharma Receives IND Clearance From FDA For Drug Candidate LP-284

Exscientia Announces AI Drug Discovery Collab With Merck KGaA, Darmstadt, Germany

PeptiDream Announces Collaboration & License Agreement With Genentech

Biofourmis Accelerates & Simplifies Drug Dev With Exp Digital Clinical Trials Solution

Unravel Announces rareSHIFT, An End-To-End Solution For Drug Discovery

Neurocrine Biosciences Announces U.S. FDA Accepts NDA For INGREZZA

Matchmaking (With AI) To Help Proteins Pair Up

Computational Model Helps With Diabetes Drug Design

New Target To Beat Cancer Drug Resistance


High-Energy Chemistry

Highly Potent Active Pharmaceutical Ingredients (HPAPIs)

Is The Sensitivity Of Optical Biosensors Important?


Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.